Risk of Clostridium difficile Infection in Hospitalized Patients Receiving Metronidazole for a Non-C difficile Infection

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 11, 2014, Pages 1856-1861

  Rodriguez, Sandra ^a   Hernandez, Marlow B ^a   Tarchini, Giorgio ^a   Zaleski, Megan ^a   Vatanchi, Marjon ^a   Cardona, Lyssette ^a   Castro Pavia, Fernando ^a   Schneider, Alison ^a  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

Antibiotic; Diarrhea; Prevention; Prophylaxis

Indexed keywords

CIPROFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PROTON PUMP INHIBITOR; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; FEMALE; HIGH RISK PATIENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; FLORIDA; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; RISK ASSESSMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; CROSS INFECTION; FEMALE; FLORIDA; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84908230239     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.02.040     Document Type: Article

References (34)

1. Barbut F., Jones G., Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. Curr Opin Infect Dis 2011, 24:370-376.
2. Ho M.Y.D., Wyle F.A., Mulligan M.E. Increased incidence of Clostridium difficile-associated diarrhea following decreased restriction of antibiotic use. Clin Infect Dis 1996, 23:102-106.
3. Privitera G., Scarpellini P., Ortisi G., et al. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 1991, 35:208-210.
4. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006, 145:758-764.
5. Gravel D., Miller M., Simor A., et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009, 48:568-576.
6. Miller M., Gravel D., Mulvey M., et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010, 50:194-201.
7. McDonald L.C., Owings M., Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006, 12:409.
8. Ghantoji S.S., Sail K., Lairson D.R., et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. JHosp Infect 2010, 74:309-318.
9. Loo V.G., Bourgault A., Poirier L., et al. Host and pathogen factors for Clostridium difficile infection and colonization. NEngl J Med 2011, 18:1693-1703.
10. Fashner J., Garcia M., Ribble L., et al. Clinical inquiry: what risk factors contribute to C difficile diarrhea?. JFam Pract 2011, 60:545-547.
11. Pépin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41:1254-1260.
12. Carignan A., Allard C., Pépin J., et al. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis 2008, 46:1838-1843.
13. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
14. Howell M.D., Novack V., Grgurich P., et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010, 170:784-790.
15. Aseeri M., Schroeder T., Kramer J., et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008, 9:2308-2313.
16. Janarthanan S., Ditahl I., Adler D.G., et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012, 107:1001-1010.
17. Kwok C.S., Arthur A.K., Anibueze C.I., et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012, 107:1011-1019.
18. Wilcox M.H., Fawley W.N., Wigglesworth N., et al. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. JHosp Infect 2003, 54:109-114.
19. Chalmers J.D., Al-Khairalla M., Short P.M., et al. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. JAntimicrob Chemother 2010, 65:608-618.
20. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep 2005, 54:1201-1205. Centers for Disease Control and Prevention.
21. Nguyen G.C., Kaplan G.G., Harris M.L., et al. Anational survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008, 103:1443-1450.
22. Ananthakrishnan A. Excess hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008, 57:205-210.
23. Price J., Cheek E., Lippett S., et al. Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis. Clin Microbiol Infect 2010, 16:1297-1302.
24. Abbett S.K., Yokoe D.S., Lipsitz S.R., et al. Proposed checklist of hospital interventions to decrease the incidence of healthcare associated Clostridium difficile infection. Infect Control Hosp Epidemiol 2009, 30:1062-1069.
25. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006, 101:812-822.
26. Johnston B.C., Ma S.S.Y., Goldenberg J.Z., et al. Probiotics for theprevention of Clostridium difficile-associated diarrhea. A systematic review and meta-analysis. Ann Intern Med 2012, 12:878-888.
27. Johnston B.C., Goldenberg J.Z., Vandvik P.O., et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011, 11:CD004827.
28. Allen S., Wareham K., Wang D., et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013, 382:1249-1257.
29. Marcobal A., Underwood M.A., Mills D.A. Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. JPediatr Gastroenterol Nutr 2008, 46:608-611.
30. Munoz P., Bouza E., Cuenca-Estrella M., et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005, 40:1625-1634.
31. Salminen M.K., Rautelin H., Tynkkynen S., et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004, 38:62-69.
32. Olson M.M., Shanholtzer C.J., Lee J.T., et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994, 15:371-381.
33. Doernberg S.B., Winston L.G., Deck D.H., et al. Does doxycycline protect against development of Clostridium difficile infection?. Clin Infect Dis 2012, 55:615-620.
34. Al-Nassir W., Sethi A., Li Y., et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008, 52:2403-2406.